Comparison of clinical findings between patients with OM-CMML and CMML
| Characteristic . | OM-CMML (n = 40) . | CMML (n = 56) . | d-CMML (n = 40) . | p-CMML (n = 16) . | P (OM-CMML vs CMML) . | P (OM-CMML vs d-CMML) . | P (OM-CMML vs p-CMML) . | P (d-CMML vs p-CMML) . |
|---|---|---|---|---|---|---|---|---|
| Age, median (range), y | 77.5 (44-91) | 76.5 (60-94) | 76.5 (60-88) | 77 (61-94) | .997 | .95 | .913 | .835 |
| Male sex, n (%) | 27 (68) | 29 (52) | 21 (52.5) | 8 (50) | .124 | .171 | .222 | .866 |
| Hemoglobin, median (range), g/L | 11.35 (7.3-14.6) | 12.3 (5.4-15.7) | 12.55 (8.6-15.7) | 11.85 (5.4-14.6) | .019 | .005 | .650 | .198 |
| WBC count, median (range), ×109/L | 4.58 (2.49-7.02) | 9.03 (2.81-34.82) | 7.95 (2.81-12.62) | 17.11 (13.18-34.82) | < .001 | < .001 | < .001 | < .001 |
| Neutrophil count, median (range), ×109/L | 2.15 (0.38-4.42) | 4.86 (0.47-19.62) | 3.35 (0.47-7.02) | 8.77 (4.67-19.62) | < .001 | < .001 | < .001 | < .001 |
| Platelet count, median (range), ×109/L | 138.5 (36-318) | 138.5 (15-559) | 137 (33-559) | 140 (15-294) | .565 | .462 | .986 | .618 |
| Monocyte count, median (range), ×109/L | 0.71 (0.53-0.96) | 1.96 (1-13.33) | 1.67 (1-3.01) | 5.02 (2.69-13.33) | <.001 | <.001 | <.001 | <.001 |
| PB monocyte %, median (range) | 17 (10-26) | 24.85 (13-60) | 23.85 (13-42) | 28.7 (20-60) | <.001 | <.001 | <.001 | .002 |
| BM monocyte %, median (range) | 5 (1-13) | 10 (2-27) | 9 (2-16) | 12 (2-27) | <.001 | <.001 | .001 | .175 |
| BM promonocyte %, median (range) | 1 (0-6) | 3 (0-14) | 2 (0-7) | 4 (1-14) | <.001 | <.001 | <.001 | .012 |
| BM blast %, median (range) | 3 (0-8) | 3 (1-15) | 3 (1-9) | 4 (1-15) | .838 | .798 | .338 | .252 |
| Dyserythropoiesis, median (range), % | 31 (0-80) | 23 (0-90) | 22 (0-90) | 24 (3-77) | .04 | .026 | .411 | .252 |
| ≥10%, % | 74 | 42.7 | 71.4 | 80 | .027 | .03 | .329 | .728 |
| Dysgranulopoiesis, median (range), % | 46 (0-100) | 44 (0-92) | 40 (0-92) | 55 (9-78) | .917 | .636 | .530 | .233 |
| ≥10%, % | 87.2 | 88.5 | 86.5 | 93.3 | 1 | .929 | 1 | .659 |
| Dysthrombopoiesis, median (range), % | 13 (0-64) | 8 (0-69) | 7 (0-69) | 16 (0-54) | .15 | .063 | .794 | .142 |
| ≥10%, % | 65.7 | 46.7 | 42.9 | 60 | .089 | .055 | .726 | .476 |
| Karyotype, abnormal/total cases (%) | 10/38 (26) | 9/50 (18) | 7/36 (19.4) | 2/14 (14.3) | .498 | .482 | .475 | .99 |
| Spanish cytogenetic risk group, n (%) | .384 | .559 | .546 | .809 | ||||
| Low | 33 (87) | 45 (90) | 32 (88.9) | 13 (92.9) | ||||
| Intermediate | 3 (8) | 1 (2) | 1 (2.8) | 0 (0) | ||||
| High | 2 (5) | 4 (8) | 3 (8.3) | 1 (7.1) | ||||
| Presence PB blasts, n (%) | 2/40 (5) | 8/50 (16) | 3/36 (8.3) | 5/15 (33.3) | .176 | .663 | .013 | .039 |
| 2017 WHO classification, n (%) | .013 | .121 | .002 | .023 | ||||
| CMML-0 | 22 (55) | 13 (25) | 12 (32.4) | 1 (6.7) | .003 | .078 | .002 | .078 |
| CMML-1 | 14 (35) | 29 (56) | 21 (56.8) | 8 (53.3) | .048 | .055 | .354 | .822 |
| CMML-2 | 4 (10) | 10 (19) | 4 (10.8) | 6 (40) | .256 | .99 | .018 | .024 |
| Patients with an associated autoimmune disease, n (%)* | 4 (10) | 5 (9) | 4 (10) | 1 (6.3) | .99 | .99 | .99 | .99 |
| Number of patients with mutations (%) | 40 (100) | 52/53 (98) | 36/37 (97.3) | 16 (100) | .99 | .481 | .99 | .99 |
| Number of mutated genes, median (range) | 2 (1-8) | 3 (0-5) | 2 (0-5) | 4 (2-5) | .407 | .46 | .001 | <.001 |
| Number of mutations, median (range) | 3 (1-9) | 3 (0-9) | 3 (0-9) | 4.5 (2-7) | .134 | .859 | .002 | .003 |
| Characteristic . | OM-CMML (n = 40) . | CMML (n = 56) . | d-CMML (n = 40) . | p-CMML (n = 16) . | P (OM-CMML vs CMML) . | P (OM-CMML vs d-CMML) . | P (OM-CMML vs p-CMML) . | P (d-CMML vs p-CMML) . |
|---|---|---|---|---|---|---|---|---|
| Age, median (range), y | 77.5 (44-91) | 76.5 (60-94) | 76.5 (60-88) | 77 (61-94) | .997 | .95 | .913 | .835 |
| Male sex, n (%) | 27 (68) | 29 (52) | 21 (52.5) | 8 (50) | .124 | .171 | .222 | .866 |
| Hemoglobin, median (range), g/L | 11.35 (7.3-14.6) | 12.3 (5.4-15.7) | 12.55 (8.6-15.7) | 11.85 (5.4-14.6) | .019 | .005 | .650 | .198 |
| WBC count, median (range), ×109/L | 4.58 (2.49-7.02) | 9.03 (2.81-34.82) | 7.95 (2.81-12.62) | 17.11 (13.18-34.82) | < .001 | < .001 | < .001 | < .001 |
| Neutrophil count, median (range), ×109/L | 2.15 (0.38-4.42) | 4.86 (0.47-19.62) | 3.35 (0.47-7.02) | 8.77 (4.67-19.62) | < .001 | < .001 | < .001 | < .001 |
| Platelet count, median (range), ×109/L | 138.5 (36-318) | 138.5 (15-559) | 137 (33-559) | 140 (15-294) | .565 | .462 | .986 | .618 |
| Monocyte count, median (range), ×109/L | 0.71 (0.53-0.96) | 1.96 (1-13.33) | 1.67 (1-3.01) | 5.02 (2.69-13.33) | <.001 | <.001 | <.001 | <.001 |
| PB monocyte %, median (range) | 17 (10-26) | 24.85 (13-60) | 23.85 (13-42) | 28.7 (20-60) | <.001 | <.001 | <.001 | .002 |
| BM monocyte %, median (range) | 5 (1-13) | 10 (2-27) | 9 (2-16) | 12 (2-27) | <.001 | <.001 | .001 | .175 |
| BM promonocyte %, median (range) | 1 (0-6) | 3 (0-14) | 2 (0-7) | 4 (1-14) | <.001 | <.001 | <.001 | .012 |
| BM blast %, median (range) | 3 (0-8) | 3 (1-15) | 3 (1-9) | 4 (1-15) | .838 | .798 | .338 | .252 |
| Dyserythropoiesis, median (range), % | 31 (0-80) | 23 (0-90) | 22 (0-90) | 24 (3-77) | .04 | .026 | .411 | .252 |
| ≥10%, % | 74 | 42.7 | 71.4 | 80 | .027 | .03 | .329 | .728 |
| Dysgranulopoiesis, median (range), % | 46 (0-100) | 44 (0-92) | 40 (0-92) | 55 (9-78) | .917 | .636 | .530 | .233 |
| ≥10%, % | 87.2 | 88.5 | 86.5 | 93.3 | 1 | .929 | 1 | .659 |
| Dysthrombopoiesis, median (range), % | 13 (0-64) | 8 (0-69) | 7 (0-69) | 16 (0-54) | .15 | .063 | .794 | .142 |
| ≥10%, % | 65.7 | 46.7 | 42.9 | 60 | .089 | .055 | .726 | .476 |
| Karyotype, abnormal/total cases (%) | 10/38 (26) | 9/50 (18) | 7/36 (19.4) | 2/14 (14.3) | .498 | .482 | .475 | .99 |
| Spanish cytogenetic risk group, n (%) | .384 | .559 | .546 | .809 | ||||
| Low | 33 (87) | 45 (90) | 32 (88.9) | 13 (92.9) | ||||
| Intermediate | 3 (8) | 1 (2) | 1 (2.8) | 0 (0) | ||||
| High | 2 (5) | 4 (8) | 3 (8.3) | 1 (7.1) | ||||
| Presence PB blasts, n (%) | 2/40 (5) | 8/50 (16) | 3/36 (8.3) | 5/15 (33.3) | .176 | .663 | .013 | .039 |
| 2017 WHO classification, n (%) | .013 | .121 | .002 | .023 | ||||
| CMML-0 | 22 (55) | 13 (25) | 12 (32.4) | 1 (6.7) | .003 | .078 | .002 | .078 |
| CMML-1 | 14 (35) | 29 (56) | 21 (56.8) | 8 (53.3) | .048 | .055 | .354 | .822 |
| CMML-2 | 4 (10) | 10 (19) | 4 (10.8) | 6 (40) | .256 | .99 | .018 | .024 |
| Patients with an associated autoimmune disease, n (%)* | 4 (10) | 5 (9) | 4 (10) | 1 (6.3) | .99 | .99 | .99 | .99 |
| Number of patients with mutations (%) | 40 (100) | 52/53 (98) | 36/37 (97.3) | 16 (100) | .99 | .481 | .99 | .99 |
| Number of mutated genes, median (range) | 2 (1-8) | 3 (0-5) | 2 (0-5) | 4 (2-5) | .407 | .46 | .001 | <.001 |
| Number of mutations, median (range) | 3 (1-9) | 3 (0-9) | 3 (0-9) | 4.5 (2-7) | .134 | .859 | .002 | .003 |
Bold P values are statistically significant.
WBC, white blood cell; Spanish cytogenetic risk group: low, normal, and isolated Y chromosome loss; intermediate, other abnormalities except those mentioned in low- and high-risk categories; and high, +8, abnormalities of chromosome 7 and complex karyotype (≥3 abnormalities).
Four patients with OM-CMML presented with a concomitant autoimmune disease: 1, antiphospholipid syndrome; 2, systemic scleroses; and 1, immune thrombocytopenic purpura. Five patients with CMML presented with a concomitant autoimmune disease: 1, systemic sclerosis; 1, dermatomyositis; 1, ankylosing spondylitis HLA-B27+; 1, antiphospholipid syndrome; 1, immune thrombocytopenic purpura.